Please use this identifier to cite or link to this item: http://hdl.handle.net/10884/484
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRamalhete, Cátia-
dc.contributor.authorCruz, Ana Filipa-
dc.contributor.authorMulhovo, Silva-
dc.contributor.authorPrudêncio, Miguel-
dc.contributor.authorFerreira, Maria José-
dc.date.accessioned2012-03-06T13:45:22Z-
dc.date.available2012-03-06T13:45:22Z-
dc.date.issued2011-
dc.identifier.citation59th International Congress and Annual Meeting of the Society for Medicinal Plant Research and Natural Product Researchpt_PT
dc.identifier.urihttp://hdl.handle.net/10884/484-
dc.description.abstractMalaria is one of the foremost public health problems in Africa. It is endemic in 90 countries, affecting nearly 40% of the global population. The increasing prevalence of drug-resistant Plasmodium falciparum strains is one of the greatest challenges in malaria control. In order to overcome drug-resistance, new antimalarial drugs are urgently needed. Most of the available antimalarial agents kill blood stage parasites and only a limited number of drugs act on liver stages. In fact, the study of Plasmodium liver stage development (Fig. 1) has been hampered by limitations in the experimental approaches required to quantify hepatocyte infection by the parasite. Therefore, the development of new drugs targeting Plasmodium liver stages represents an important and underexploited site of intervention [1, 2].-
dc.language.isoengpt_PT
dc.rightsopenAccessen
dc.subjectTriterpenoidspt_PT
dc.subjectPlasmodiumpt_PT
dc.titleTriterpenoids as inhibitors of Plasmodium liver-stage developmentpt_PT
dc.typeconferenceObjectpt_PT
Appears in Collections:A CS/CN - Comunicações a Conferências

Files in This Item:
File Description SizeFormat 
2011_Antalia_Malaria.pdf1.3 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.